In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immunicon nets $51.34mm with IPO

Executive Summary

Diagnostics company Immunicon has netted $51.34mm with an IPO of 6.9mm common shares (including the overallotment) priced at $8 each. The company had originally hoped to bring in $86.25mm, pricing the shares at between $12-14 each.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies